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Genome-wide significant association between a
‘negative mood delusions’ dimension in bipolar
disorder and genetic variation on chromosome 3q26.1
S Meier1, M Mattheisen2,3,4, E Vassos5, J Strohmaier1, J Treutlein1, F Josef1, R Breuer1, F Degenhardt2,6, TW Mu¨hleisen2,6,
B Mu¨ller-Myhsok7, M Steffens8, C Schmael1, FJ McMahon9, Bipolar Disorder Genome Study (BiGS) Consortium13, MM No¨then2,6,10,
S Cichon2,6,11, TG Schulze12,14 and M Rietschel1,14
Research suggests that clinical symptom dimensions may be more useful in delineating the genetics of bipolar disorder (BD)
than standard diagnostic models. To date, no study has applied this concept to data from genome-wide association studies
(GWAS). We performed a GWAS of factor dimensions in 927 clinically well-characterized BD patients of German ancestry.
Rs9875793, which is located in an intergenic region of 3q26.1 and in the vicinity of the solute carrier family 2 (facilitated glucose
transporter), member 2 gene (SLC2A2), was significantly associated with the factor analysis-derived dimension ‘negative mood
delusions’ (n¼ 927; P¼ 4.65 10 8, odds ratio (OR)¼ 2.66). This dimension was comprised of the symptoms delusions of
poverty, delusions of guilt and nihilistic delusions. In case–control analyses, significant association with the G allele of
rs9875793 was only observed in the subgroup of BD patients who displayed symptoms of ‘negative mood delusions’ (allelic v2
model: PG¼ 0.0001, OR¼ 1.92; item present, n¼ 89). Further support for the hypothesis that rs9875793 is associated with BD in
patients displaying ‘negative mood delusions’ symptom, such as delusions of guilt, was obtained from an European American
sample (GAIN/TGEN), which included 1247 BD patients and 1434 controls (PEA¼ 0.028, OR¼ 1.27).
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Introduction
Bipolar disorder (BD) is a severe psychiatric condition that is
characterized by fundamental and distinctive distortions of
emotion regulation and perception. BD has an equal sex
incidence, affects all age groups and has a worldwide lifetime
prevalence of approximately 1%. Family and twin studies of
BD have provided unequivocal evidence that inherited genetic
variation contributes substantially to disease risk,1–3 and
genome-wide association studies (GWAS) have identified
several risk variants.4–8 Further analyses of these data have
suggested that the risk of BD has a substantial polygenic
component, involving a large number of common risk alleles
of small effect.9
Previous studies of genetic risk for BD have been based on
a categorical diagnosis. However, genes that act through
specific biological mechanisms are unlikely to have a similar
influence on all BD symptoms, and thus association signals
for more specific BD subtypes may have been missed. This
hypothesis is supported by findings from previous BD studies.
In linkage studies, subphenotyping BD patients according to
relevant selected features led to the identification of potential
susceptibility loci specific to psychotic BD,10–13 BD with
comorbid anxiety10 and BD with attention deficit hyperactivity
disorder symptoms.14 In candidate gene studies, NRG1,15
5-HTTLPR16 and COMT17 have been implicated in BD with
psychotic symptoms, whereas DAOA has been implicated in
BD with persecutory delusions.18
The aim of the present study was to test the hypotheses
that symptom dimensions derived through a factor analysis
approach that takes into account variations in core, and
associated symptoms would enable the formation of geneti-
cally more homogenous BD subgroups, and that analysis of
these subgroups would identify associations missed in GWAS
of the broad BD phenotype, despite a reduction in sample
size. The GWAS step was performed in BD patients of
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German ancestry, and the top findings were followed-up in an
European American BD sample.
Materials and methods
Sample ascertainment and genotyping. All participants
provided written informed consent. The study protocols were
approved by the respective institutional review boards or
ethics committees.
German sample. The German sample was used in a
previous GWAS,8 and in a study exploring copy number
variation of a categorical diagnosis of BD.19 These references
provide a detailed description of the sampling and genotyping
procedures. In brief, the present study included 927 in-
patients with a DSM-IV diagnosis of BD and 2168 control
subjects, all of German ancestry (for sample description see
Table 1). The BD diagnoses were assigned on the basis of
multiple sources of information, including the German version
of the Structured Clinical Interview for DSM-IV axis I disorders
(SCID-I),20 the Operational Criteria Checklist for Psychotic
Illness (OPCRIT v3.32),21 medical records and family history.
All study participants were individually genotyped using
Illumina HumanHap550v3 BeadChips, Illumina Human610-
Quad Beadchips or Illumina Human660Quad BeadChips
(Illumina, Inc., San Diego, CA, USA). Following stringent
quality control, the final GWAS data set was comprised of
378 570 single-nucleotide polymorphisms (SNPs) with a
minor allele frequency of at least 10%.
European American sample. A detailed description of the
sample and the genotyping procedure is provided else-
where.22 The GAIN/TGEN sample included 1247 patients
with a best estimate DSM IV diagnosis of either bipolar I
disorder or schizoaffective disorder bipolar subtype based on
the Diagnostic Interview for Genetic Studies
(DIGS 4.0)23 and 1434 controls. All the study participants
were of European American ancestry and were genotyped
using the Affymetrix Genome-Wide Human SNP Array 6.0
(Santa Clara, CA, USA) (Figure 1).
Factor analysis and the use of factors as binary traits for
the association study. To refine the phenotypic character-
ization of the German BD sample (n¼ 970), we performed a
principal component analysis of 48 clinical OPCRIT items
(Supplementary Table 1). From this analysis, we derived 12
factor dimensions. In contrast to other rating scales, the
OPCRIT has neither a positive nor a negative symptom
subscale, either of which might bias symptom rating. Factors
derived from OPCRIT ratings are therefore less likely to be
statistical artifacts of scale development. Genotypic data
were available for 927 of these patients, and these patients
were therefore included in the present study. The OPCRIT
items referred to appearance and behavior, speech, form of
thought, affect, and abnormal beliefs. Missing data varied
from approximately 0.8 (excessive activity, suicidal ideation)
to 9% (increased sociability). Missing values were replaced
by the median for the specific item, taking into account the
ordinal characteristic of the OPCRIT data.
We inspected our data to determine whether it would be
reasonable to conduct an orthogonal principal component
analysis. The Kaiser–Meyer–Olkin (KMO) criterion measures
the covariance of variables.24 Values above 0.6 indicate
variables that are suitable for factor analysis. In our BD data,
the KMO sampling adequacy was 0.855. Factor dimensions
were extracted according to the commonly used Kaiser–
Guttman criterion,25 resulting in a 12-factor solution. Fulfil-
ment of the Kaiser–Guttman criterion indicates that a factor
analysis-derived dimension explains more of the variance in
clinical symptoms than any single clinical symptom alone.
This 12-factor solution explained 54.2% of the total variance
in the BD sample. For each patient, a personal regression
factor score was calculated for each dimension. The
12-factor dimensions derived in the BD sample were termed:
‘depression’, ‘mania’, ‘delusions’, ‘grandiose delusions’, ‘deper-
sonalization’, ‘voices’, ‘agitation’, ‘disorganization’, ‘other hallu-
cinations’, ‘negative mood delusions’, ‘catatonia’ and ‘negative
symptoms’ (see Supplementary Tables 2 and 3).
As the factor dimensions failed to display a normal
distribution, the factor scores were transformed to binary
Table 1 Descriptive data for the German bipolar disorder patients
German sample
Investigated individuals 927
Males 428
Males (%) (46.2%)
Mean age at recruitment in years (s.d.) 44.0 (13.59)
Mean age of onset in years (s.d.) 27.7 (11.27)
Abbreviation: s.d., standard deviation.
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Figure 1 Quantile–quantile (QQ) plot of the genome-wide association data. QQ
plot of allelic w2 test P values from autosomal SNPs following the application of all
quality control filters. Good adherence of data points to the line of expectance was
observed. This implies that spurious associations, characterized by an increase in
the number of potential highly significant P values, had been systematically
removed. All remaining slight deviations from the line of expectance in the extreme
tail are presumed to reflect true-positive genetic effects.
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format. Factor scores ofX1.0 were rated as ‘high scores’, and
factor scores of p1.0 as ‘low scores’. A low score indicates
that almost none of the items loading on that particular factor
were observed in the patient. Each factor dimension was
present in around 15% of the BD patients. As all SNPs with a
minor allele frequency of X0.1 were included, only factor
dimensions present in at least 25 patients from the German
sample were analyzed, as expected cell frequencies of o5
would violate one of the premises of the w2 test. Eleven
factor dimensions fulfilled this criterion (‘mania’, ‘delusions’,
‘grandiose delusions’, ‘depersonalization’, ‘voices’, ‘agitation’,
‘disorganization’, ‘other hallucinations’, ‘negative mood delu-
sions’, ‘catatonia’ and ‘negative symptoms’), and were there-
fore included in the dimensional GWAS.
Statistical analyses for the GWAS and follow-up study.
All association analyses were performed using PLINK26
(v1.07). In the single-marker analysis, all of the autosomal
SNPs that passed quality control checks were tested for
association with the 11 binary factor dimensions using the
allelic w2 model and the Armitage trend test. The P values
were corrected using the genomic inflation factor. A P-value
of o5 10 8 per trait was selected as the threshold for
genome-wide significance,27,28 under the assumption of the
presence of one million non-correlated common SNPs in the
genome. Adjustment for the number of traits tested appeared
too conservative, as factor dimensions were intercorrelated
(Supplementary Table 4).
We then explored whether genome-wide significant var-
iants were associated with the categorical diagnosis of BD
per se or primarily with a specific BD subphenotype. For this
purpose, we tested for association in the entire sample, in
subgroups of patients with and without symptoms from the
‘negative mood delusions’ dimension and in a control cohort.
In addition, these findings were followed up in an independent
European American sample of BD patients. Given that a
different diagnostic instrument had been employed in the
European American sample, we attempted to find support for
our findings on the basis of symptoms rather than factor
dimensions. Symptoms with a factor loading of 0.32 (that is,
10% of shared variance between variable and factor) were
considered to contribute to the specific factor dimension.29
TheP values of the follow-up sample were corrected using the
genomic inflation factor.
Results
Factor analysis resulted in a 12-factor solution. Eleven factor
dimensions fulfilled the statistical premises for inclusion in the
GWAS (‘mania’, ‘delusions’, ‘grandiose delusions’, ‘deperso-
nalization’, ‘voices’, ‘agitation’, ‘disorganization’, ‘other hallu-
cinations’, ‘negative mood delusions’, ‘catatonia’ and
‘negative symptoms’; see Supplementary Tables 2 and 3).
The association between the rs9875793 G allele and the
factor dimension ‘negative mood delusions’ (delusions of
poverty, delusions of guilt and nihilistic delusions, see
Supplementary Table 5) surpassed the threshold for gen-
ome-wide significance of Po5 10 8 under the assumption
of an allelic w2 model (PG¼ 4.65 10 8, odds ratio
(OR)¼ 2.66; factor present, n¼ 88). One additional SNP—
rs1499821—showed a trend towards genome-wide signifi-
cance (PG¼ 5.8 10 8, OR¼ 2.65; factor present, n¼ 88).
Rs9875793 is located in the vicinity of the solute carrier family
2 (facilitated glucose transporter), member 2 gene SLC2A2.
Rs1499821, which is in complete linkage disequilibrium
(D 0 ¼ 1.0, r2¼ 0.925) with rs9875793, is located within this
gene. Analysis of the seven intragenic SLC2A2 SNPs
represented on the array revealed that four (rs5398,
rs1499821, rs8192675, rs11924032) were significantly asso-
ciated with the factor dimension ‘negative mood delusions’
(Po0.05, with Bonferroni correction for seven SNPs) in the
combined sample (see Table 2, Figure 2). Association with
rs9875793 was only found for ‘negative mood delusions’. No
nominally significant association was found with any other
factor dimension.
Exploration of the association in the entire sample and in
subgroups of patients with and without symptoms from the
‘negative mood delusions’ dimension in comparison to a
control cohort (n¼ 2168) revealed that a significant associa-
tion with the G allele of rs9875793 was only present in the
subgroup of patients with ‘negative mood delusions’ symptom
(n¼ 89) (allelic w2 model: PG¼ 0.0001, OR¼ 1.92).
The only ‘negative mood delusions’ symptom rated in the
European American follow-up sample (GAIN/TGEN) was
Table 2 Associations between the factor dimension ‘negative mood delusions’ and rs9875793 and the seven SLC2A2 SNPs in the German GWAS sample
(see Figure 2)
SNP data Association data
German sample
Allelic w2 model MAF
Marker Chromosome Alleles Factor dimension PG OR High scores Low scores
rs9875793 3 A/G Negative mood delusions 4.65 10 8 2.66 0.27 0.12
rs10513684 3 T/C Negative mood delusions NS 1.06 0.04 0.04
rs10513685 3 A/G Negative mood delusions NS 0.71 0.10 0.14
rs1499821 3 A/G Negative mood delusions 5.80 10 8 2.65 0.27 0.12
rs8192675 3 G/A Negative mood delusions 0.0017 1.68 0.37 0.26
rs5400 3 T/C Negative mood delusions NS 0.71 0.10 0.14
rs11924032 3 A/G Negative mood delusions 0.00017 1.87 0.34 0.22
Abbreviations: MAF, minor allele frequency; NS, non significant; OR, odds ratio referring to minor allele; SNPs, single-nucleotide polymorphisms.
Alleles, minor/major allele. Minor allele refers to dbSNP build129, and was determined in each analysis in patients with and patients without the trait.
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delusions of guilt or sin. This corresponds to delusions of guilt
in the German sample (item present, n¼ 83; mapping 93% of
the patients with the ‘negative mood delusions’ symptom).
This symptom also showed significant association with the G
allele in a separate single item analysis (allelic w2 model:
PG¼ 0.0008, OR¼ 1.87; see Supplementary Table 6). This
association in the European American sample was in the
same direction as that identified in the German sample (allelic
w2 model:PEA¼ 0.028, OR¼ 1.27). In the European American
BD sample, no such association was observed in either the
total sample or in patients without this symptom, in compar-
ison to controls (see Supplementary Table 7).
Discussion
To our knowledge, the present GWAS of BD is the first to be
based on factor analysis-derived symptom dimensions. We
hypothesized that subsampling of patients according to selected
clinical features would enable identification of novel genetic
associations that would be missed in analyses of a broad BD
phenotype. Using this new approach, we were able to identify a
genome-wide significant association between the factor dimen-
sion ‘negative mood delusions’ (delusions of poverty, delusions
of guilt and nihilistic delusions) and the chromosome 3 variant
rs9875793 (PG¼ 4.65 10 8, OR¼ 2.66).
Rs9875793 is located in an intergenic region on chromo-
some 3, approximately 28 kb downstream of the glucose
transporter gene SLC2A2. The cortically expressed SLC2A2
gene30 is a promising candidate gene for BD, as it is involved in
the lithium-sensitive phosphatidyl inositol pathway,31 and its
expression is modulated by psychological stress.32 Addition-
ally, our top SNP rs9875793 was recently reported to be
associated with differing activity of the right dorsolateral
prefrontal cortex during a working memory paradigm in
patients with schizophrenia in comparison to healthy
controls.33 The dorsolateral prefrontal cortex is a critical
interface between emotion regulation and cognition, and is
particularly involved in the processing of negative emo-
tions.34,35 Structural and functional abnormalities in this region
have been reported in patients with BD, schizophrenia and
major depression.33,36,37
Case–control analyses revealed a unique association
between the G allele of rs9875793 and BD patients with
‘negative mood delusions’ compared with controls, and this
association was also observed in an independent European
American BD sample. The fact that not even a trend toward
association with the G allele of rs9875793 was observed for
the categorical diagnosis of BD may suggest that patients with
‘negative mood delusions’ symptom constitute a biologically
more homogenous BD subgroup.
The present results indicate that BD patients characterized
by the factor dimension ‘negative mood delusions’ may
represent a genetically more homogenous subgroup. A
limitation of the present study is that no stringent adjustment
was made for the number of factor dimensions included.
However, as our finding gained further support in the follow-up
study, we consider our finding to be robust. The present study
also underlines the feasibility of the factor dimensional
approach, as it allows subphenotyping in clinical practice.
Screening for the presence of particular symptoms might
allow the identification of genetically more homogenous BD
subgroups, which may in turn facilitate the development of
individual treatment strategies.
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Figure 2 Regional-association plots displaying rs9875793 and the SCL2A2 SNPs. Allelic w2 test P values from SNPs are plotted against positions from the March 2006
human reference sequence, annotated by RefSeq genes. The most highly associated marker from the combined analysis (P) is indicated by an enlarged red diamond, which is
in the center of a genomic window of around 300 Mb. The strength of linkage disequilibrium (in r 2) between the top SNP and its adjacent markers is demonstrated by the red
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